[1]
|
Busch, R. (1990) On the History of Cystic Fibrosis. Acta Universitatis Carolinae, 36, 13-15.
|
[2]
|
Blasius, G.L., Heiland, M., Hoffmann, M. and Wolfgang, A. (1677) Gerardii Blasii Amstelodamensis Observationes Medicae Rariores: Accedit Monstri Triplicis Historia. Apud Abrahamum Wolfgang. https://books.google.com/books?id=QyfHzgEACAAJ
|
[3]
|
Łysiak, M. (2008) From Guild Surgery to Ludwik Rydygier Surgical Clinic Collegium Medicum, Nicholas Copernicus University in Toruń. Polish Journal of Surgery, 80, 227-230. https://doi.org/10.2478/v10035-008-0028-z
|
[4]
|
Frías, J., Ruiz, E., López Castillo, M. and García, P. (2019) The History of Cystic Fibrosis. Open Journal of Pediatrics and Child Health, 4, 1-6. https://doi.org/10.17352/ojpch.000015
|
[5]
|
Rokitansky, K. (1846) Handbuch der Pathologischen Anatomie: Handbuch der Allgemeinen Pathologischen Anatomie. Legare Street Press, London.
|
[6]
|
Andersen, D. (1938) Cystic Fibrosis of the Pancreas and Its Relation to Celiac Disease: A Clinical and Pathologic Study. The American Journal of Diseases of Children, 56, 344-399. https://doi.org/10.1001/archpedi.1938.01980140114013
|
[7]
|
Bodian, M. (1953) Fibrocystic Disease of the Pancreas: A Congenital Disorder of Mucus Production-Mucosis. Grune & Stratton, New York.
|
[8]
|
Knowles, M., Gatzy, J. and Boucher, R. (1981) Increased Bioelectric Potential Difference across Respiratory Epithelia in Cystic Fibrosis. The New England Journal of Medicine, 305, 1489-1495. https://doi.org/10.1056/NEJM198112173052502
|
[9]
|
Quinton, P.M. (1983) Chloride Impermeability in Cystic Fibrosis. Nature, 301, 421-422. https://doi.org/10.1038/301421a0
|
[10]
|
Gadsby, D.C., Vergani, P. and Csanády, L. (2006) The ABC Protein Turned Chloride Channel Whose Failure Causes Cystic Fibrosis. Nature, 440, 477-483. https://doi.org/10.1038/nature04712
|
[11]
|
Corradi, V., Vergani, P. and Tieleman, D.P. (2015) Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): Closed and Open State Channel Models. Journal of Biological Chemistr, 290, 22891-22906. https://doi.org/10.1074/jbc.M115.665125
|
[12]
|
Moskowitz, S.M., Chmiel, J.F., Sternen, D.L., Cheng, E., Gibson, R.L., Marshall, S.G., et al. (2008) Clinical Practice and Genetic Counseling for Cystic Fibrosis and CFTR-Related Disorders. Genetics in Medicine, 10, 851-868. https://doi.org/10.1097/GIM.0b013e31818e55a2
|
[13]
|
Chen, Q., Shen, Y. and Zheng, J. (2021) A Review of Cystic Fibrosis: Basic and Clinical Aspects. Animal Models and Experimental Medicine, 4, 220-232. https://doi.org/10.1002/ame2.12180
|
[14]
|
Abou Tayoun, A.N., Tunkey, C.D., Pugh, T.J., Ross, T., Shah, M., Lee, C.C., et al. (2013) A Comprehensive Assay for CFTR Mutational Analysis Using Next-Generation Sequencing. Clinical Chemistry, 59, 1481-1488. https://doi.org/10.1373/clinchem.2013.206466
|
[15]
|
Aghamohammadi, A., Keivanfar, M., Navaei, S., Shirzadi, R., Masiha, F., Allameh, Z., et al. (2019) First Cystic Fibrosis Patient Registry Annual Data Report-Cystic Fibrosis Foundation of Iran. Acta Medica Iranica, 57, 33-41. https://doi.org/10.18502/acta.v57i1.1751
|
[16]
|
Riordan, J.R., Rommens, J.M., Kerem, B, Sheva Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989) Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA. Science, 245, 1066-1073. https://doi.org/10.1126/science.2475911
|
[17]
|
De Araujo, F., Novaes, F.C., Dos Santos, N., Martins, V., De, C., De Souza, S., Dos Santos, S., et al. (2005) Prevalence of DeltaF508, G551D, G542X, and R553X Mutations among Cystic Fibrosis Patients in the North of Brazil. Brazilian Journal of Medical and Biological Research, 38, 11-15. https://doi.org/10.1590/S0100-879X2005000100003
|
[18]
|
Tsui, L.C. (1992) The Spectrum of Cystic Fibrosis Mutations. Trend in Genetics, 8, 392-398. https://doi.org/10.1016/0168-9525(92)90168-4
|
[19]
|
MacKenzie, T., Gifford, A.H., Sabadosa, K.A., Quinton, H.B., Knapp, E.A., Goss, C.H., et al. (2014) Longevity of Patients with Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry. Annals of Internal Medicine, 161, 233-241. https://doi.org/10.7326/M13-0636
|
[20]
|
Debray, D., Narkewicz, M.R., Bodewes, F.A.J.A., Colombo, C., Housset, C., De Jonge, H.R., et al. (2017) Cystic Fibrosis-Related Liver Disease: Research Challenges and Future Perspectives. Journal of Pediatric Gastroenterology and Nutrition, 65, 443-448. https://journals.lww.com/jpgn/fulltext/2017/10000/cystic_fibrosis_related_liver_disease__research.23.aspx https://doi.org/10.1097/MPG.0000000000001676
|
[21]
|
Bhaskar, R.K., Turner, B.S., Grubman, S.A., Jefferson, D.M. and LaMont, J.T. (1998) Dysregulation of Proteoglycan Production by Intrahepatic Biliary Epithelial Cells Bearing Defective (Delta-F508) Cystic Fibrosis Transmembrane Conductance Regulator. Hepatology, 27, 7-14. https://doi.org/10.1002/hep.510270103
|
[22]
|
Colombo, C. (2007) Liver Disease in Cystic Fibrosis. Current Opinion in Pulmonary Medicine, 13, 529-536. https://journals.lww.com/co-pulmonarymedicine/fulltext/2007/11000/liver_disease_in_cystic_fibrosis.11.aspx https://doi.org/10.1097/MCP.0b013e3282f10a16
|
[23]
|
Lewindon, P.J., Shepherd, R.W., Walsh, M.J., Greer, R.M., Williamson, R., Pereira, T.N., et al. (2011) Importance of Hepatic Fibrosis in Cystic Fibrosis and the Predictive Value of Liver Biopsy. Hepatology, 53, 193-201. https://doi.org/10.1002/hep.24014
|
[24]
|
Kristidis, P., Bozon, D., Corey, M., Markiewicz, D., Rommens, J., Tsui, L., et al. (1992) Genetic Determination of Exocrine Pancreatic Function in Cystic Fibrosis. The American Journal of Human Genetics, 50, 1178-1184.
|
[25]
|
Abu-El-Haija, M., Ramachandran, S., Meyerholz, D.K., Abu-El-Haija, M., Griffin, M., Giriyappa, R.L., et al. (2012) Pancreatic Damage in Fetal and Newborn Cystic Fibrosis Pigs Involves the Activation of Inflammatory and Remodeling Pathways. The American Journal of Pathology, 181, 499-507. https://doi.org/10.1016/j.ajpath.2012.04.024
|
[26]
|
Wilschanski, M. and Novak, I. (2013) The Cystic Fibrosis of Exocrine Pancreas. Cold Spring Harbor Perspectives in Medicine, 3, a009746. https://doi.org/10.1101/cshperspect.a009746
|
[27]
|
Nousia-Arvanitakis, S. (1999) Cystic Fibrosis and the Pancreas: Recent Scientific Advances. Journal of Clinical Gastroenterology, 29, 138-142. https://journals.lww.com/jcge/fulltext/1999/09000/cystic_fibrosis_and_the_pancreas__recent.7.aspx https://doi.org/10.1097/00004836-199909000-00007
|
[28]
|
Lee, M.G., Ohana, E., Park, H.W., Yang, D. and Muallem, S. (2012) Molecular Mechanism of Pancreatic and Salivary Gland Fluid and HCO3− Secretion. Physiological Reviews, 92, 39-74. https://doi.org/10.1152/physrev.00011.2011
|
[29]
|
Park, H.W. and Lee, M.G. (2012) Transepithelial Bicarbonate Secretion: Lessons from the Pancreas. Cold Spring Harbor Perspectives in Medicine, 2, a009571. https://doi.org/10.1101/cshperspect.a009571
|
[30]
|
Granados, A., Chan, C.L., Ode, K.L., Moheet, A., Moran, A. and Holl, R. (2019) Cystic Fibrosis Related Diabetes: Pathophysiology, Screening and Diagnosis. Journal of Cystic Fibrosis, 18, S3-S9. https://doi.org/10.1016/j.jcf.2019.08.016
|
[31]
|
Coderre, L., Debieche, L., Plourde, J., Rabasa-Lhoret, R. and Lesage, S. (2021) The Potential Causes of Cystic Fibrosis-Related Diabetes. Frontiers in Endocrinology, 12, Article 702823. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.702823 https://doi.org/10.3389/fendo.2021.702823
|
[32]
|
Hussein, T., Zakaria, N. and Zahran, A. (2011) Clinical, Laboratory and Genetic Assessment of Patients with Congenital Bilateral Absent Vas Deferens. Andrologia, 43, 16-22. https://doi.org/10.1111/j.1439-0272.2009.01001.x
|
[33]
|
De Souza, D.A.S., Faucz, F.R., Pereira-Ferrari, L., Sotomaior, V.S. and Raskin, S. (2018) Congenital Bilateral Absence of the Vas Deferens as an Atypical Form of Cystic Fibrosis: Reproductive Implications and Genetic Counseling. Andrology, 6, 127-135. https://doi.org/10.1111/andr.12450
|
[34]
|
Salwan, A. and Abdelrahman, A. (2017) Congenital Absence of Vas Deferens and Ectopic Kidney. International Journal of Surgery Case Reports, 34, 90-92. https://doi.org/10.1016/j.ijscr.2017.03.019
|
[35]
|
Chillón, M., Casals, T., Mercier, B., Bassas, L., Lissens, W., Silber, S., et al. (1995) Mutations in the Cystic Fibrosis Gene in Patients with Congenital Absence of the Vas Deferens. The New England Journal of Medicine, 332, 1475-1480. https://doi.org/10.1056/NEJM199506013322204
|
[36]
|
Bieth, E., Hamdi, S.M. and Mieusset, R. (2021) Genetics of the Congenital Absence of the Vas Deferens. Human Genetics, 140, 59-76. https://doi.org/10.1007/s00439-020-02122-w
|
[37]
|
Xu, W.M., Shi, Q.X., Chen, W.Y., Zhou, C.X., Ni, Y., Rowlands, D.K., et al. (2007) Cystic Fibrosis Transmembrane Conductance Regulator Is Vital to Sperm Fertilizing Capacity and Male Fertility. Proceedings of the National Academy of Sciences of the United States of America, 104, 9816-9821. https://doi.org/10.1073/pnas.0609253104
|
[38]
|
Yang, L., Ren, Z., Yang, B., Zhou, J., Peng, Z., Fang, K., et al. (2020) The Association Between Variants in the CFTR Gene and Nonobstructive Male Infertility: A Meta-Analysis. Andrologia, 52, e13475. https://doi.org/10.1111/and.13475
|
[39]
|
Gaillard, D.A., Carre-Pigeon, F. and Lallemand, A. (1997) Normal Vas Deferens in Fetuses with Cystic Fibrosis. gy, 158, 1549-1552. https://doi.org/10.1016/S0022-5347(01)64278-2
|
[40]
|
Cuppens, H. and Cassiman, J. (2004) CFTR Mutations and Polymorphisms in Male Infertility. International Journal of Andrology, 27, 251-256. https://doi.org/10.1111/j.1365-2605.2004.00485.x
|
[41]
|
Gelfond, D., Ma, C., Semler, J. and Borowitz, D. (2013) Intestinal PH and Gastrointestinal Transit Profiles in Cystic Fibrosis Patients Measured by Wireless Motility Capsule. Digestive Diseases and Sciences, 58, 2275-2281. https://doi.org/10.1007/s10620-012-2209-1
|
[42]
|
Barraclough, M. and Taylor, C. (1996) Twenty-Four Hour Ambulatory Gastric and Duodenal PH Profiles in Cystic Fibrosis: Effect of Duodenal Hyperacidity on Pancreatic EnzymeFunction and Fat Absorption. Journal of Pediatric Gastroenterology and Nutrition, 23, 45-50. https://doi.org/10.1002/j.1536-4801.1996.tb00301.x
|
[43]
|
De Lisle, R.C. and Borowitz, D. (2013) The Cystic Fibrosis Intestine. Cold Spring Harbor Perspectives in Medicine, 3, a009753. https://doi.org/10.1101/cshperspect.a009753
|
[44]
|
Mavilia, M.G. and Pope, S. (2018) Distal Intestinal Obstructive Syndrome (DIOS): A Gastrointestinal Complication of Cystic Fibrosis in Adults: 1490. American Journal of Gastroenterology, 113, S855-S856. https://doi.org/10.14309/00000434-201810001-01490
|
[45]
|
Cotter, P.D. (2011) Small Intestine and Microbiota. Current Opinion in Gastroenterology, 27, 99-105. https://doi.org/10.1097/MOG.0b013e328341dc67
|
[46]
|
Singh, V.V. and Toskes, P.P. (2004) Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment. Current Treatment Options in Gastroenterology, 7, 19-28. https://doi.org/10.1007/s11938-004-0022-4
|
[47]
|
Smith, J.J., Travis, S.M., Greenberg, E.P. and Welsh, M.J. (1996) Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface Fluid. Cell, 85, 229-236. https://doi.org/10.1016/S0092-8674(00)81099-5
|
[48]
|
Travis, S.M., Conway, B.A.D., Zabner, J., Smith, J.J., Anderson, N.N., Singh, P.K., et al. (1999) Activity of Abundant Antimicrobials of the Human Airway. American Journal of Respiratory Cell and Molecular Biology, 20, 872-879. https://doi.org/10.1165/ajrcmb.20.5.3572
|
[49]
|
Matsui, H., Grubb, B.R., Tarran, R., Randell, S.H., Gatzy, J.T., Davis, C.W., et al. (1998) Evidence for Periciliary Liquid Layer Depletion, Not Abnormal Ion Composition, in the Pathogenesis of Cystic Fibrosis Airways Disease. Cell, 95, 1005-1015. https://doi.org/10.1016/S0092-8674(00)81724-9
|
[50]
|
Mall, M., Bleich, M., Greger, R., Schreiber, R. and Kunzelmann, K. (1998) The Amiloride-Inhibitable Na Conductance Is Reduced by the Cystic Fibrosis Transmembrane Conductance Regulator in Normal but Not in Cystic Fibrosis Airways. Journal of Clinical Investigation, 102, 15-21. https://doi.org/10.1172/JCI2729
|
[51]
|
Wine, J.J. (1999) The Genesis of Cystic Fibrosis Lung Disease. Journal of Clinical Investigation, 103, 309-312. https://doi.org/10.1172/JCI6222
|
[52]
|
Pezzulo, A.A., Tang, X.X., Hoegger, M.J., Abou, Alaiwa, M.H., Ramachandran, S., Moninger, T.O., et al. (2012) Reduced Airway Surface PH Impairs Bacterial Killing in the Porcine Cystic Fibrosis Lung. Nature, 487, 109-113. https://doi.org/10.1038/nature11130
|
[53]
|
Cantin, A.M., Hartl, D., Konstan, M.W. and Chmiel, J.F. (2015) Inflammation in Cystic Fibrosis Lung Disease: Pathogenesis and Therapy. Journal of Cystic Fibrosis, 14, 419-430. https://doi.org/10.1016/j.jcf.2015.03.003
|
[54]
|
Abou Alaiwa, M.H., Reznikov, L.R., Gansemer, N.D., Sheets, K.A., Horswill, A.R., Stoltz, D.A., et al. (2014) PH Modulates the Activity and Synergism of the Airway Surface Liquid Antimicrobials β-Defensin-3 and LL-37. Proceedings of the National Academy of Sciences of the United States of America, 111, 18703-18708. https://doi.org/10.1073/pnas.1422091112
|
[55]
|
Lomunova Gershovich, P.M. (2023) Gene Therapy for Cystic Fibrosis: Recent Advances and Future Prospects. Acta Naturae, 15, 20-31. https://doi.org/10.32607/actanaturae.11708
|
[56]
|
Burgener, E.B. and Moss, R.B. (2018) Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Precision Medicine in Cystic Fibrosis. Current Opinion in Pediatrics, 30, 372-377. https://doi.org/10.1097/MOP.0000000000000627
|
[57]
|
Boyd, A.C., Guo, S., Huang, L., Kerem, B., Oren, Y.S., Walker, A.J. and Hart, S.L. (2020) New Approaches to Genetic Therapies for Cystic Fibrosis. Journal of Cystic Fibrosis, 19, S54-S59. https://doi.org/10.1016/j.jcf.2019.12.012
|
[58]
|
Yan, Z., McCray, P.B. and Engelhardt, J.F. (2019) Advances in Gene Therapy for Cystic Fibrosis Lung Disease. Human Molecular Genetics, 28, R88-R94. https://doi.org/10.1093/hmg/ddz139
|
[59]
|
Cooney, A.L., McCray, P.B. and Sinn, P.L. (2018) Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes, 9, Article 538. https://doi.org/10.3390/genes9110538
|
[60]
|
Cao, H., Ouyang, H., Grasemann, H., Bartlett, C., Du, K., Duan, R., et al. (2018) Transducing Airway Basal Cells with a Helper-Dependent Adenoviral Vector for Lung Gene Therapy. Human Gene Therapy, 29, 643-652. https://doi.org/10.1089/hum.2017.201
|
[61]
|
Hsu, P.D., Lander, E.S. and Zhang, F. (2014) Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell, 157, 1262-1278. https://doi.org/10.1016/j.cell.2014.05.010
|
[62]
|
Hille, F. and Charpentier, E. (2016) CRISPR-Cas: Biology, Mechanisms and Relevance. Philosophical Transactions of the Royal Society B: Biological Sciences, 371, Article ID: 20150496. https://doi.org/10.1098/rstb.2015.0496
|
[63]
|
Hall, B., Cho, A., Limaye, A., Cho, K., Khillan, J. and Kulkarni, A.B. (2018) Genome Editing in Mice Using CRISPRCas9 Technology. Current Protocols in Cell Biology, 81, e57. https://doi.org/10.1002/cpcb.57
|
[64]
|
Everson, E.M., Olzsko, M.E., Leap, D.J., Hocum, J.D. and Trobridge, G.D. (2016) 1. A Direct Comparison of Foamy and Lentiviral Vector Genotoxicity in SCID-Repopulating Cells Shows Foamy Vectors Are Less Prone to Clonal Dominance. Molecular Therapy, 24, S1. https://doi.org/10.1038/mt.2016.78
|
[65]
|
Hodges, C.A. and Conlon, R.A. (2019) Delivering on the Promise of Gene Editing for Cystic Fibrosis. Genes and Diseases, 6, 97-108. https://doi.org/10.1016/j.gendis.2018.11.005
|
[66]
|
Zhang, Y., Long, C., Li, H., Mcanally, J.R., Baskin, K.K., Shelton, J.M., et al. (2017) CRISPR-Cpf1 Correction of Muscular Dystrophy Mutations in Human Cardiomyocytes and Mice. Science Advances, 3, e1602814. https://www.science.org https://doi.org/10.1126/sciadv.1602814
|
[67]
|
Katz, M.G., Fargnoli, A.S. and Bridges, C.R. (2013) Myocardial Gene Transfer: Routes and Devices for Regulation of Transgene Expression by Modulation of Cellular Permeability. Human Gene Therapy, 24, 375-392. https://doi.org/10.1089/hum.2012.241
|
[68]
|
Lentz, T.B., Gray, S.J. and Samulski, R.J. (2012) Viral Vectors for Gene Delivery to the Central Nervous System. Neurobiology of Disease, 48, 179-188. https://doi.org/10.1016/j.nbd.2011.09.014
|
[69]
|
Atchison, R.W., Casto, B.C. and Hammon, W.M. (1965) Adenovirus-Associated Defective Virus Particles. Science, 149, 754-756.
|
[70]
|
Kantor, B., Bailey, R.M., Wimberly, K., Kalburgi, S.N. and Gray, S.J. (2014) Methods for Gene Transfer to the Central Nervous System. Advances in Genetics, 87, 125-197. https://doi.org/10.1016/B978-0-12-800149-3.00003-2
|
[71]
|
Guggino, W.B. and Cebotaru, L. (2017) Adeno-Associated Virus (AAV) Gene Therapy for Cystic Fibrosis: Current Barriers and Recent Developments. Expert Opinion on Biological Therapy, 17, 1265-1273. https://doi.org/10.1080/14712598.2017.1347630
|
[72]
|
Steines, B., Dickey, D.D., Bergen, J., Excoffon, K.J.D.A., Weinstein, J.R., Li, X., et al. (2016) CFTR Gene Transfer with AAV Improves Early Cystic Fibrosis Pig Phenotypes. JCI Insight, 1, e88728. https://doi.org/10.1172/jci.insight.88728
|
[73]
|
Vidovic, D., Carlon, M.S., Da Cunha, M.F., Dekkers, J.F., Hollenhorst, M.I., Bijvelds, M.J.C., et al. (2016) RAAV-CFTRDR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice. American Journal of Respiratory and Critical Care Medicine, 193, 288-298. https://doi.org/10.1164/rccm.201505-0914OC
|
[74]
|
Wille, P., Rosenjack, J., Cotton, C., Kelley, T., Padegimas, L. and Miller, T. (2019) EPS1.02 Identification of AAV Developed for Cystic Fibrosis Gene Therapy That Restores CFTR Function in Human Cystic Fibrosis Patient Cells. Journal of Cystic Fibrosis, 18, S39-S56. https://doi.org/10.1016/S1569-1993(19)30241-3
|
[75]
|
Marquez Loza, L.I., Yuen, E.C. and McCray, P.B. (2019) Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease. Genes, 10, Article 218. https://doi.org/10.3390/genes10030218
|
[76]
|
Cooney, A.L., Abou Alaiwa, M.H., Shah, V.S., Bouzek, D.C., Stroik, M.R., Powers, L.S., et al. (2016) Lentiviral-Mediated Phenotypic Correction of Cystic Fibrosis Pigs. JCI Insight, 1, e88730. https://doi.org/10.1172/jci.insight.88730
|
[77]
|
Alton, E.W.F.W., Beekman, J.M., Boyd, A.C., Brand, J., Carlon, M.S., Connolly, M.M., et al. (2017) Preparation for a First-In-Man Lentivirus Trial in Patients with Cystic Fibrosis. Thorax, 72, 137-147. https://doi.org/10.1136/thoraxjnl-2016-208406
|
[78]
|
Burney, T.J. and Davies, J.C. (2012) Gene Therapy for the Treatment of Cystic Fibrosis. Application of Clinical Genetics, 5, 29-36. https://doi.org/10.2147/TACG.S8873
|
[79]
|
Rowe, S.M., Zuckerman, J.B., Dorgan, D., Lascano, J., McCoy, K., Jain, M., et al. (2023) Inhaled MRNA Therapy for Treatment of Cystic Fibrosis: Interim Results of A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Clinical Study. Journal of Cystic Fibrosis, 22, 656-664. https://doi.org/10.1016/j.jcf.2023.04.008
|
[80]
|
Da Silva Sanchez, A., Paunovska, K., Cristian, A. and Dahlman, J.E. (2020) Treating Cystic Fibrosis with MRNA and CRISPR. Human Gene Therapy, 31, 940-955. https://doi.org/10.1089/hum.2020.137
|
[81]
|
Marangi, M. and Pistritto, G. (2018) Innovative Therapeutic Strategies for Cystic Fibrosis: Moving forward to CRISPR Technique. Frontiers in Pharmacology, 9, Article 396. https://doi.org/10.3389/fphar.2018.00396
|
[82]
|
Jaques, R., Shakeel, A. and Hoyle, C. (2020) Novel Therapeutic Approaches for the Management of Cystic Fibrosis. Multidisciplinary Respiratory Medicine, 15, Article No. 690.
|
[83]
|
Gaj, T., Gersbach, C.A. and Barbas, C.F. (2013) ZFN, TALEN, and CRISPR/Cas-Based Methods for Genome Engineering. Trends in Biotechnology, 31, 397-405. https://doi.org/10.1016/j.tibtech.2013.04.004
|
[84]
|
Roundtree, I.A., Evans, M.E., Pan, T. and He, C. (2017) Dynamic RNA Modifications in Gene Expression Regulation. Cell, 169, 1187-1200. https://doi.org/10.1016/j.cell.2017.05.045
|
[85]
|
Ramanathan, A., Robb, G.B. and Chan, S.H. (2016) MRNA Capping: Biological Functions and Applications. Nucleic Acids Research, 44, 7511-7526. https://doi.org/10.1093/nar/gkw551
|